Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.
Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ. Vandepapeliere P, et al. Among authors: wettendorff m. J Infect Dis. 2005 Dec 15;192(12):2099-107. doi: 10.1086/498164. Epub 2005 Nov 11. J Infect Dis. 2005. PMID: 16288373 Clinical Trial.
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C; Therapeutic HBV Vaccine Group of Investigators. Vandepapelière P, et al. Among authors: wettendorff m. Vaccine. 2007 Dec 12;25(51):8585-97. doi: 10.1016/j.vaccine.2007.09.072. Epub 2007 Oct 24. Vaccine. 2007. PMID: 18031872 Clinical Trial.
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G. Vandepapelière P, et al. Among authors: wettendorff m. Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14. Vaccine. 2008. PMID: 18272264 Clinical Trial.
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
Leroux-Roels G, Van Belle P, Vandepapeliere P, Horsmans Y, Janssens M, Carletti I, Garçon N, Wettendorff M, Van Mechelen M. Leroux-Roels G, et al. Among authors: wettendorff m. Vaccine. 2015 Feb 18;33(8):1084-91. doi: 10.1016/j.vaccine.2014.10.078. Epub 2014 Nov 7. Vaccine. 2015. PMID: 25444781 Free article.
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Dessy FJ, et al. Among authors: wettendorff ma. Hum Vaccin. 2008 Nov-Dec;4(6):425-34. doi: 10.4161/hv.4.6.6912. Epub 2008 Nov 11. Hum Vaccin. 2008. PMID: 18948732
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA. Giannini SL, et al. Among authors: wettendorff ma. Vaccine. 2006 Aug 14;24(33-34):5937-49. doi: 10.1016/j.vaccine.2006.06.005. Epub 2006 Jun 19. Vaccine. 2006. PMID: 16828940
27 results